Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

Impacts of Inflammatory Cytokines Variants on Systemic Inflammatory Profile and COVID-19 Severity

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration

Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

The roles of critical pro‐inflammatory cytokines in the drive of cytokine storm during SARS‐CoV‐2 infection

The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm

The cytokine storm and COVID‐19

The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?

Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis

Implications on Eating Behaviors and Nutritional Status

Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper

Potential marker subset of blood-circulating cytokines on hematopoietic progenitor-to-Th1 pathway in COVID-19

Targeting Inflammation and Cytokine Storm in COVID-19

Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality

Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage COVID-19 Infection

Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses